Use access key #2 to skip to page content.
  • S&P 500: 1,090.34
  • Change: -0.11%
$3.96 0.07 (1.80%)
11/30/2009 2:40 PM

AMERICAN ORIENTL BIO (AOB)

CAPS Rating:
*****

The Company, together with its wholly owned subsidiaries, is a pharmaceutical and Traditional Chinese Medicine company which develops, manufactures and commercializes both plant-based pharmaceutical and plant-based nutraceutical products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating AOB

Add Stock to Watchlist

What the Community Thinks

Total Members

3034 Outperforms
94 Underperforms
 

All-Stars

858 Outperforms
31 Underperforms
 

Wall Street

4 Outperforms
1 Underperforms
 

Members bullish on AOB are also bullish on:

Members bearish on AOB are also bearish on:

Ticker Tags

Consumer Staples (231), Personal Products (35), Value (1896), Micro Cap (4813), Defensive (1498), China (228), Drug Manufacturers - Major (4), International Stock (694), Nutraceuticals (2)
Suggest a tag

AMERICAN ORIENTL BIO At A Glance

Current Price: $3.96
Last Trade Time: 11/30/2009 2:40 PM
Open: $3.92
Previous Close: $3.89
Daily Range: $3.89 - $3.98
52-Week Range: $3.29 - $7.66
Volume: 530,932
Market Cap: $310.15M
P/E Ratio: 7.41
Compare Our Special Broker Offers!

Stock Trends

AOB VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

10

AMERICAN ORIENTL BIO (AOB)

Avatar mrindependent (98.95) Submitted: 10/01/09 5:39 PM

According to Jubak, the Chinese government is making a substantial push to expand the country's healthcare sector. American Oriental Biology ought to benefit from this initiative. The price is right at 1.04 times book value and 6 times estimated earnings in 2010 (i.e. $0.77 per share). The balanc...More

Replies: 3 | Reply | Permalink

Top Bear Pitch

Recs

1

AMERICAN ORIENTL BIO (AOB)

Avatar zotten (90.77) Submitted: 11/13/09 9:15 PM

I suggest people read the following blog:

http://seekingalpha.com/article/172921-american-oriental-bioengineering-questionable-acquisitions

I do not like what I read. I will stay clear.

Replies: 2 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 468 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (AOB)

Avatar Fourtrak (88.58) Submitted: 11/23/09 12:37 PM : Outperform Start Price: $3.77 AOB Score: 6.92

I got in after earnings release on this one. It was apparent it would be rare for them to meet expectations, so I expected a drop and got it. China plays are tough, they do not do business like us and there is a lot of speculation on mismanagement. I see it doing well once the economic jitters are out of the way, and as long as they get a handle on expenses, it looks like they misread the economy and spent far too much for the level of sales they got. It appears to me to be a mistake made by management, but certainly fixable.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (AOB)

Avatar jackbot (37.83) Submitted: 11/19/09 2:56 PM : Outperform Start Price: $3.79 AOB Score: 5.24

Tough to see what's wrong here.

I haven't done extensive research, but earnings look good, margins are great (>15%), and debt about equal to cash.

May pick this up for real.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (AOB)

Avatar 00100 (96.39) Submitted: 11/16/09 3:28 PM : Outperform Start Price: $4.24 AOB Score: -4.84

Upthumb. Traditional medicine products in China. Excellent cash flow. Huge sales growth. Low to nominal debt ratio. Lots of cash on-hand. Ascencio short with large short ratio. Ascencio doesn't like their lack of disclosure of subsidiaries.

Report this Post Replies: 1 | Reply | Permalink

Recs

1

 (AOB)

Avatar zotten (90.77) Submitted: 11/13/09 9:15 PM : Underperform Start Price: $4.14 AOB Score: 3.01

I suggest people read the following blog:

http://seekingalpha.com/article/172921-american-oriental-bioengineering-questionable-acquisitions

I do not like what I read. I will stay clear.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (AOB)

Avatar bevbur (< 20) Submitted: 11/13/09 11:13 AM : Underperform Start Price: $4.03 AOB Score: 1.05

We have own this stock...it has continued to underperform for a long time. I believe it has underlying problems.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 468 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackBreanMurray 85.72 11/30/09 Outperform NS $3.92+1.53%-0.08%+1.61
TrackMerriman < 20 01/12/09 Outperform NS $5.29-24.76%+25.36%-50.13
TrackRothCapital 73.51 12/30/08 Outperform NS $6.34-37.22%+26.83%-64.05
TrackJefferies < 20 11/21/07 Outperform NS $10.65-62.63%-19.86%-42.77
TrackJimCramer 59.79 06/06/06 Underperform 3W $5.52-27.90%-7.78%+20.12

Results 1 - 5 of 5  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 140ms